Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
05 2019
Historique:
received: 19 07 2018
revised: 26 11 2018
accepted: 02 01 2019
pubmed: 12 3 2019
medline: 27 5 2020
entrez: 12 3 2019
Statut: ppublish

Résumé

We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng), neurofilament light (NFL), YKL-40, and total tau (T-tau). We included 770 individuals with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD)-type dementia from the EMIF-AD Multimodal Biomarker Discovery study. We tested the association of Ng, NFL, YKL-40, and T-tau with Aβ status (Aβ- vs. Aβ+), clinical diagnosis APOE ε4 carriership, baseline cognition, and change in cognition. Ng and T-tau distinguished between Aβ+ from Aβ- individuals in each clinical group, whereas NFL and YKL-40 were associated with Aβ+ in nondemented individuals only. APOE ε4 carriership did not influence NFL, Ng, and YKL-40 in Aβ+ individuals. NFL was the best predictor of cognitive decline in Aβ+ individuals across the cognitive spectrum. Axonal degeneration, synaptic dysfunction, astroglial activation, and altered tau metabolism are involved already in preclinical AD. NFL may be a useful prognostic marker.

Identifiants

pubmed: 30853464
pii: S1552-5260(19)30018-4
doi: 10.1016/j.jalz.2019.01.004
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Apolipoprotein E4 0
Biomarkers 0
Neurofilament Proteins 0
tau Proteins 0
Neurogranin 132654-77-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

644-654

Informations de copyright

Copyright © 2019 the Alzheimer's Association. All rights reserved.

Auteurs

Isabelle Bos (I)

Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands. Electronic address: isabelle.bos@maastrichtuniversity.nl.

Stephanie Vos (S)

Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.

Frans Verhey (F)

Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.

Philip Scheltens (P)

Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands.

Charlotte Teunissen (C)

Neurochemistry Lab and Biobank, Department of Clinical Chemistry, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands.

Sebastiaan Engelborghs (S)

Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

Kristel Sleegers (K)

Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium.

Giovanni Frisoni (G)

University of Geneva, Geneva, Switzerland; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Olivier Blin (O)

Mediterranean Institute of Cognitive Neuroscience, Aix Marseille University, Marseille, France.

Jill C Richardson (JC)

Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK.

Régis Bordet (R)

University of Lille, Inserm, CHU Lille, Lille, France.

Magda Tsolaki (M)

1st Department of Neurology, AHEPA University Hospital, Makedonia, Thessaloniki, Greece.

Julius Popp (J)

Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Geneva, Switzerland; Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland.

Gwendoline Peyratout (G)

Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland.

Pablo Martinez-Lage (P)

Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain.

Mikel Tainta (M)

Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain.

Alberto Lleó (A)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Peter Johannsen (P)

Danish Dementia Research Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Yvonne Freund-Levi (Y)

Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden; Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Psychiatry Norrtälje Hospital Tiohundra, Norrtäije, Sweden.

Lutz Frölich (L)

Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.

Rik Vandenberghe (R)

University Hospital Leuven, Leuven, Belgium.

Sarah Westwood (S)

University of Oxford, Oxford, United Kingdom.

Valerija Dobricic (V)

Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany.

Frederik Barkhof (F)

Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering, University College London, London, UK.

Cristina Legido-Quigley (C)

Steno Diabetes Center, Copenhagen, Denmark; King's College London, London, UK.

Lars Bertram (L)

Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany; School of Public Health, Imperial College London, London, UK; Department of Psychology, University of Oslo, Oslo, Norway.

Simon Lovestone (S)

University of Oxford, Oxford, United Kingdom.

Johannes Streffer (J)

Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Early Clinial Neurology, UCB Biopharma SPRL, Braine-l'Alleud, Belgium.

Ulf Andreasson (U)

Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden.

Kaj Blennow (K)

Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden.

Henrik Zetterberg (H)

Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; UK Dementia Research Institute, London, UK.

Pieter Jelle Visser (PJ)

Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands; Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH